DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR IN SERUM AND TISSUE OF PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Pistola, L. [1 ]
Ludovini, V. [1 ]
Gregorc, V. [2 ]
Bellezza, G. [3 ]
Darwish, S. [1 ]
Rulli, E. [4 ]
Compagnoni, A. [4 ]
Sidoni, A. [3 ]
Scheibel, M. [3 ]
Myhailova, Z. [1 ]
Ragusa, M. [5 ]
Di Carlo, L. [5 ]
Tofanetti, F. R. [1 ]
Bellet, M. M. [1 ]
Ferraldeschi, M. [1 ]
Daddi, G. [5 ]
Tonato, M. [1 ]
机构：
[1] Med Oncol Azienda Osped, Perugia, Italy
[2] S Raffaele Sci Inst, Div Oncol, Milan, Italy
[3] Univ Perugia, Inst Pathol, I-06100 Perugia, Italy
[4] Biometry Unit Oncol Ist Mario Negri, Milan, Italy
[5] Azienda Osped, Dept Thorac Surg, Perugia, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [31] The plasma level of soluble epidermal growth factor Receptor (EGFR) and overall survival (OS) in non-small-cell lung cancer (NSCLC) patients.
    Ye, Ping
    Zhao, Jing
    Wang, Shulian
    Kong, Feng Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Value of serum epidermal growth factor receptor in the selection of patients with non-small-cell lung cancer to be treated with the tyrosine kinase inhibitor erlotinib
    Ventosa, E. Y. R.
    Prieto, S. B.
    Vazquez-Iglesias, L.
    Castro, L. B.
    Berrocal, F. J. R.
    Santos, I. A.
    Paez de la Cadena, M.
    FEBS JOURNAL, 2012, 279 : 116 - 116
  • [33] Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor
    Fujiuchi, S
    Ohsaki, Y
    Kikuchi, K
    ONCOLOGY, 1997, 54 (02) : 134 - 140
  • [34] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    Liu, G.
    Gurubhagavatula, S.
    Zhou, W.
    Wang, Z.
    Yeap, B. Y.
    Asomaning, K.
    Su, L.
    Heist, R.
    Lynch, T. J.
    Christiani, D. C.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (02): : 129 - 138
  • [35] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Liao, Bin-Chi
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Chen, Ya-Fang
    Chang, Chin-Hao
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1754 - 1761
  • [36] Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer
    Gisondi, Paolo
    Geat, Davide
    Mattiucci, Alessandra
    Lombardo, Fiorella
    Santo, Antonio
    Girolomoni, Giampiero
    DERMATOLOGY, 2021, 237 (06) : 929 - 933
  • [37] Epidermal Growth Factor Receptor Mutations Effect on Volume Doubling Time of Non-Small-Cell Lung Cancer Patients
    Nakamura, Ryota
    Inage, Yoshihisa
    Tobita, Rika
    Mori, Kazuko
    Numata, Takeshi
    Yanai, Hidetoshi
    Endo, Takeo
    Ohtani, Haruo
    Satoh, Hiroaki
    Yuzawa, Kenji
    Koizumi, Masanori
    Ueki, Hamaichi
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : 1340 - 1344
  • [38] Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer
    Martin, Juliane
    Lehmann, Annika
    Klauschen, Frederick
    Hummel, Michael
    Lenze, Dido
    Grohe, Christian
    Tessmer, Ante
    Gottschalk, Joachim
    Schmidt, Berndt
    Pau, Hans-Wilhelm
    Witt, Christian
    Moegling, Stefan
    Kromminga, Robert
    Joehrens, Korinna
    CLINICAL LUNG CANCER, 2019, 20 (05) : 350 - +
  • [39] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    G Liu
    S Gurubhagavatula
    W Zhou
    Z Wang
    B Y Yeap
    K Asomaning
    L Su
    R Heist
    T J Lynch
    D C Christiani
    The Pharmacogenomics Journal, 2008, 8 : 129 - 138
  • [40] Management of Brain Metastases in epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
    Kelly, William J.
    Shah, Neil J.
    Subramaniam, Deepa S.
    FRONTIERS IN ONCOLOGY, 2018, 8
12345